California-based biopharma company Alumis has unveiled compelling data from its pivotal Phase III ONWARD program for envudeucitinib, a novel tyrosine kinase 2 (TYK2) inhibitor. The results, demonstrating significant and durable efficacy in plaque psoriasis, position envudeucitinib as a potential contender in an increasingly crowded oral treatment landscape. Alumis anticipates filing a New Drug Application (NDA) with the US Food and Drug Administration (FDA) in the fourth quarter of 2026, setting the stage for a direct confrontation with established and emerging therapies.
The ONWARD program, comprising three robust clinical trials (ONWARD 1, ONWARD 2, and ONWARD 3), has provided a comprehensive look at envudeucitinib’s performance. The initial trials, ONWARD 1 and ONWARD 2, employed a randomized controlled design, comparing envudeucitinib against both placebo and Amgen’s established oral psoriasis medication, Otezla (apremilast). The open-label ONWARD 3 trial, meanwhile, focused on evaluating the long-term safety and efficacy of envudeucitinib in patients who had transitioned from the first two studies. These extensive trials have yielded data suggesting a leading profile for envudeucitinib, particularly in achieving substantial skin clearance, reducing itch, and improving the quality of life for patients living with plaque psoriasis.
A Chronological Journey to Promising Data
The development of envudeucitinib by Alumis has followed a strategic path, culminating in the recent release of Phase III data that fuels its regulatory ambitions. The company’s commitment to developing a differentiated oral therapy for plaque psoriasis has been evident throughout the ONWARD program.
- Early Phase Development: While specific details of Alumis’ early-phase research are not elaborated upon in the provided text, the progression to Phase III signifies successful completion of preclinical and early-stage clinical evaluations, indicating a strong safety and preliminary efficacy profile.
- Initiation of Phase III ONWARD Program: The ONWARD program represents the critical late-stage clinical development phase for envudeucitinib. The initiation of ONWARD 1, ONWARD 2, and ONWARD 3 marked a significant milestone, signaling Alumis’ confidence in the drug’s potential.
- Enrollment and Treatment in ONWARD 1 & 2: Patients with moderate to severe plaque psoriasis were enrolled in these randomized, placebo-controlled trials. The design allowed for a direct comparison of envudeucitinib’s efficacy against Otezla and a placebo, providing crucial benchmarks for its performance.
- Long-Term Assessment in ONWARD 3: The open-label ONWARD 3 study was designed to capture the sustained benefits and safety profile of envudeucitinib over an extended treatment period. Patients from ONWARD 1 and 2 who responded to treatment were eligible to enroll, offering valuable insights into the drug’s durability.
- Publication of Key Data: The recent release of data from these Phase III studies is the culmination of years of research and development. This data forms the bedrock of Alumis’ submission strategy for regulatory approval.
- Anticipated NDA Submission (Q4 2026): Alumis has publicly stated its intention to submit a New Drug Application (NDA) for envudeucitinib in plaque psoriasis by the fourth quarter of 2026. This timeline indicates a strategic approach to regulatory engagement, allowing for the comprehensive analysis and presentation of the amassed clinical evidence.
Supporting Data: A Multifaceted Approach to Efficacy
The efficacy of envudeucitinib in plaque psoriasis has been assessed across several key domains, offering a holistic view of its therapeutic impact. The data from the ONWARD program highlights significant improvements in skin clearance, itch reduction, and overall quality of life, while also underscoring a favorable safety profile.
1. Substantial and Durable Skin Clearance:
- PASI 75 Achievement: Previous findings indicated that 54% of patients treated with twice-daily envudeucitinib achieved a Psoriasis Area and Severity Index (PASI) 75 response at week 48. PASI 75 signifies at least a 75% improvement in psoriasis symptoms compared to baseline, a critical benchmark for treatment efficacy.
- Scalp Clearance: The ONWARD 3 study revealed a remarkable durability of treatment effect on the scalp, a common and often challenging area for psoriasis sufferers. At the 48-week mark, an impressive 80% of patients maintained a scalp considered clear or almost clear of psoriasis. This sustained clearance in a difficult-to-treat area is a significant indicator of envudeucitinib’s long-term benefit.
2. Clinically Meaningful Itch Reduction:
- Rapid Onset of Relief: The impact of envudeucitinib on pruritus, or itch, was observed to be swift and significant. In the ONWARD 1 and 2 studies, one in three patients treated with envudeucitinib experienced a clinically meaningful reduction in itch. Crucially, this relief was noted as early as week two, offering rapid symptomatic improvement for patients.
- Sustained Itch Relief: The positive effects on itch were not transient. The ONWARD 3 study demonstrated that 80% of patients sustained this clinically meaningful itch reduction for up to 48 weeks of treatment, highlighting the drug’s ability to provide ongoing comfort and alleviate a major burden of the disease.
3. Significant Improvement in Quality of Life (QoL):
- Minimizing Daily Impact: Psoriasis can profoundly affect a patient’s daily life. Envudeucitinib has shown a notable positive impact on this aspect. At week 12 of treatment, half of the treated patients reported that their psoriasis had minimal to no impact on their daily quality of life. This suggests a rapid and substantial improvement in their overall well-being.
- Long-Term QoL Benefits: The positive effects on quality of life were sustained over the long term. In the ONWARD 3 study, over 70% of patients maintained this minimal to no impact on their daily QoL after 48 weeks of treatment, underscoring envudeucitinib’s potential to restore a sense of normalcy to patients’ lives.
4. Favorable Safety and Tolerability Profile:
- Absence of New Safety Signals: A critical aspect of any new drug is its safety profile, especially with long-term use. The data from the ONWARD program indicated that patients tolerated envudeucitinib well. Importantly, researchers identified no new safety signals associated with long-term treatment, a reassuring finding for both patients and clinicians. This suggests a favorable risk-benefit profile for the drug.
Navigating a Competitive Psoriasis Landscape
The approval of envudeucitinib would see it enter a highly competitive market for oral psoriasis treatments. Alumis faces established players and emerging therapies, each with its own set of advantages and target patient populations.
-
Established Oral Therapies:
- Amgen’s Otezla (apremilast): As a comparator in the ONWARD trials, Otezla is a well-established oral phosphodiesterase 4 (PDE4) inhibitor used for plaque psoriasis. While effective for many, envudeucitinib’s data suggests potentially higher efficacy in certain measures.
- Bristol Myers Squibb’s Sotyktu (deucravacitinib): Sotyktu, another oral TYK2 inhibitor, has already garnered significant market share, achieving $291 million in sales last year. Alumis aims to differentiate envudeucitinib through its engineered mechanism, designed for a 24-hour inhibition of TYK2, potentially offering a more sustained therapeutic effect compared to Sotyktu’s dosing profile.
-
Emerging Oral Therapies:
- Johnson & Johnson’s Icotyde (icotrokinra): This newly approved psoriasis pill has generated considerable excitement due to its "biologic-like efficacy in a once-daily oral pill" profile, as noted by industry analysts. Icotyde’s once-daily dosing presents a significant convenience advantage over envudeucitinib’s twice-daily regimen, a factor that could influence prescribing patterns and patient preference.
- Takeda’s Investigational Zasocitinib: While not yet approved, zasocitinib is another investigational oral psoriasis drug that has been mentioned in comparison to envudeucitinib. Analysts suggest that envudeucitinib’s efficacy might be perceived as lower than both Icotyde and zasocitinib, potentially posing a challenge for its market differentiation.
The success of envudeucitinib will likely depend on its ability to demonstrate clear advantages in efficacy, safety, or patient convenience that resonate with both prescribers and patients. The twice-daily dosing regimen, while not ideal for all, may be offset by superior efficacy or a more favorable long-term safety profile.
Official Responses and Future Implications
Alumis’ proactive approach to presenting its Phase III data and outlining its regulatory pathway signals strong confidence in envudeucitinib’s potential. The company’s clear target of a Q4 2026 NDA submission demonstrates a well-defined strategy for bringing this therapy to market.
Alumis’ Perspective: The company’s emphasis on envudeucitinib’s "leading" potential underscores their belief that the drug offers a significant advancement in oral psoriasis treatment. The data highlighting sustained efficacy, rapid itch relief, and improved quality of life are key pillars of their narrative. Their focus on the 24-hour TYK2 inhibition mechanism is a strategic move to differentiate from competitors like Sotyktu.
Analyst and Market Outlook: Industry analysts are closely watching the psoriasis market, recognizing its significant commercial potential. The introduction of new oral agents like Icotyde and the continued success of Sotyktu indicate a strong demand for convenient and effective treatments. However, concerns have been raised regarding envudeucitinib’s perceived efficacy relative to newer entrants and its twice-daily dosing. These observations will undoubtedly shape market adoption if envudeucitinib gains approval.
Implications for Patients: If approved, envudeucitinib would offer another valuable oral option for patients living with plaque psoriasis. The demonstrated benefits in reducing disease severity, alleviating debilitating itch, and improving daily functioning could significantly enhance the quality of life for many. The absence of new safety signals with long-term use is particularly encouraging for patients seeking chronic disease management.
Broader Market Impact: The success of envudeucitinib could further solidify the shift towards oral therapies for moderate to severe psoriasis, potentially reducing the reliance on injectable biologics for a larger patient population. This would represent a significant evolution in how psoriasis is managed, offering greater convenience and accessibility. The competitive dynamics driven by envudeucitinib’s potential entry will likely spur further innovation and research within the field, ultimately benefiting patients through a wider array of treatment choices.
About the Author
